124 240

Cited 27 times in

The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial.

Authors
Lee, KT; Lee, DH; Yoo, BM
Citation
Pancreas, 37(4):445-448, 2008
Journal Title
Pancreas
ISSN
0885-31771536-4828
Abstract
OBJECTIVES: Patients undergoing therapeutic endoscopic retrograde cholangiopancreatography (ERCP) are at a higher risk of developing post-ERCP pancreatitis than patients undergoing diagnostic ERCP. The aim of this study was to evaluate the effectiveness of somatostatin in preventing post-therapeutic ERCP pancreatitis. METHODS: This placebo-controlled, double-blind, randomized study involved 391 patients in 3 hospitals who required therapeutic ERCP. Patients were assigned to receive either somatostatin or placebo. The incidence of pancreatitis and hyperamylasemia after performing ERCP was compared between the somatostatin and placebo groups. RESULTS: Pancreatitis occurred in statistically significantly fewer ERCP patients who received somatostatin (7/193: 3.6%) than placebo (19/198: 9.6%; P = 0.02). With regard to the individual ERCP procedures, statistically significant reductions in post-ERCP pancreatitis were seen in patients treated with somatostatin who had stoneremoval (P = 0.04) and endoscopic papillary balloon dilation (P= 0.03). The incidence of hyperamylasemia was lower in the somatostatin group (7.8%) than in the placebo group (12.6%), although this difference was not statistically significant (P > 0.05). CONCLUSIONS: A significantly lower incidence of post-ERCP pancreatitis occurred in patients who received somatostatin prophylaxis. This finding suggests that the administration of somatostatin is useful in preventing pancreatitis in patients undergoing therapeutic ERCP.
MeSH terms
AdolescentAdultAgedAged, 80 and overCholangiopancreatography, Endoscopic Retrograde/adverse effects*Double-Blind MethodFemaleHumansHyperamylasemia/etiologyHyperamylasemia/prevention & controlInfusions, ParenteralKoreaMaleMiddle AgedPancreatitis/etiologyPancreatitis/prevention & control*Premedication*Protective Agents/administration & dosage*Somatostatin/administration & dosage*Treatment OutcomeYoung Adult
DOI
10.1097/MPA.0b013e3181733721
PMID
18953260
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Gastroenterology
AJOU Authors
유병무
Full Text Link
Files in This Item:
Full-Text Not Available.txtDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse